Lupin receives tentative approval from USFDA for Raltegravir Tablets
This product will be manufactured at Lupin’s Nagpur facility in India
This product will be manufactured at Lupin’s Nagpur facility in India
The company uses iPS cells to develop treatments for diseases relating to the kidney
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Subscribe To Our Newsletter & Stay Updated